News

Foley Hoag Represents Daewoong in $336 Million Deal with CS Pharma

February 08, 2023

Foley Hoag LLP represented South Korea's Daewoong Pharmaceutical (“Daewoong”) in securing an exclusive licensing agreement with CS Pharmaceuticals, a UK based multinational company focused on the development and commercialization of rare disease and ophthalmology products in China, for a first-in-class PRS inhibitor ‘Bersiporocin’ in Greater China region, including mainland China, Hong Kong, Taiwan, and Macau.

Daewoong is developing the world's first-in-class candidate substance against idiopathic pulmonary fibrosis, 'Bersiporocin'. Under the agreement, Daewoong will grant CS Pharmaceuticals with exclusive rights for development and commercialization of Bersiporocin for the treatment of idiopathic pulmonary fibrosis and other respiratory indications.

Foley Hoag attorneys Hemmie Chang, David Halstead, John Harre, Sumantha Sedor, Anna Cardoso and Nicola Lemay represented Daewoong in the deal.